ESC 365 - Dapagliflozin effect on functional mitral regurgitation and myocardial remodeling (DEFORM trial)

ESC Professional Premium Access

Dapagliflozin effect on functional mitral regurgitation and myocardial remodeling (DEFORM trial)

Session: Valvular disease and myocardial remodelling: a dangerous liaison

Topic: Mitral Valve Regurgitation

Speaker: Doctor Z. Huang (Guangzhou, CN)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Zhuoshan Huang

Third Affiliated Hospital of Sun Yat-sen University, Guangzhou (China)

0 follower

6 more presentations in this session

Impact of single-valve and multiple-valve heart disease on long-term outcome in patients with chronic heart failure

Speaker: Doctor K. Hu (Wuerzburg, DE)

Comparison of non-invasive and invasive cardiac damage staging in patients with clinically significant aortic stenosis

Speaker: Doctor M. Belmonte (Rome, IT)

Left ventricular hypertrophy and ventricular ectopy in mitral valve prolapse

Speaker: Mr A. Cesmat (Chapel Hill, US)

Cardiac damage extent in patient with isolated severe aortic stenosis referred to surgical aortic valve replacement: is it reversible after surgery?

Speaker: Doctor M. Lima (Lisbon, PT)

Epidemiology and prognostic relevance of morphofunctional classification of secondary mitral regurgitation

Speaker: Doctor A. Provencio (Madrid, ES)

Access the full session

Valvular disease and myocardial remodelling: a dangerous liaison

Speakers: Doctor Z. Huang, Doctor K. Hu, Doctor M. Belmonte, Mr A. Cesmat, Doctor M. Lima...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources